JPMorgan analyst Chris Schott raised the firm’s price target on Teva (TEVA) to $28 from $26 and keeps an Overweight rating on the shares. The company reported solid Q3 results, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA: